First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
NCT07930338, Phase 1, Not yet recruiting, YGION Biomedical GmbH
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma | ClinicalTrials.gov |
| NCT number | NCT07930338 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1 | ClinicalTrials.gov |
| Enrollment | 15 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | YGION Biomedical GmbH | ClinicalTrials.gov |
| Conditions | Glioblastoma | ClinicalTrials.gov |
| Interventions | YG-01 Dose Level 1, YG-01 Dose Level 2 | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Incidence of local and systemic adverse events within 7 days following each administration of YG-01 | From baseline until 7 days after each YG-01 administration. | Treatment-emergent local (injection-site) and systemic adverse events, graded by NCI CTCAE v6.0, starting within 7 days after each administration. Summarized per administration and overall, by severity, seriousness and relationship to YG-01. | ClinicalTrials.gov |
| Secondary | Incidence of treatment-emergent adverse events over the study period | From baseline until study completion | All treatment-emergent adverse events during the treatment period, and YG-01-related adverse events during follow-up graded by NCI CTCAE v6.0. | ClinicalTrials.gov |
| Secondary | Progression-free survival (PFS) | From baseline until progression or death (up to 24 months) | Time from study treatment start (baseline) to tumor progression on MRI or death from any cause. | ClinicalTrials.gov |
| Secondary | Overall Survival (OS) | From baseline until death (up to 24 months) | Time from study treatment start (baseline) to death from any cause. | ClinicalTrials.gov |
| Other | Induction neoantigen-specific T-cell Responses | From Pre-Production Screening until end of study (up to 24 months) | T-cell responses against the patient-specific neoepitopes in peripheral blood, analyzed descriptively. | ClinicalTrials.gov |
| Other | Induction of YG-01-specific antibody responses | From Pre-Production Screening until end of study (up to 24 months) | Antibody responses against YG-01 in serum, analyzed descriptively. | ClinicalTrials.gov |
| Other | Induction of cytokine responses | From Pre-Production Screening until end of study (up to 24 months) | Changes in serum cytokine profiles will be assessed and analyzed descriptively. | ClinicalTrials.gov |
| Other | Cytotoxicity potential of T cells | From Pre-Production Screening until end of study (up to 24 months) | The cytotoxic activity of neoantigen-specific T cells will be assessed in vitro and analyzed descriptively. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.